Atrogi Announces First Subjects Dosed in Human Trial for Lead Candidate ATR-258 - PressReach

Atrogi announces first subjects dosed in human trial for lead candidate ATR-258 - PressReach

First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential as a novel treatment for muscle-sparing weight loss Study led by Associate Professor Morten Hostrup, a leading authority on β2-adrenergic receptor signaling in skeletal muscle at the University of Copenhagen, to evaluate muscle physiological aspects of ATR-258’s highly selective β2-adrenergic s…

Atrogi begins dosing first subjects in human trial of ATR

Study to explore mechanism behind novel oral therapy for muscle‑sparing weight loss

Atrogi announces first subjects dosed in human trial for lead candidate ATR-258

First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential as a novel treatment for muscle-sparing weight loss Study led by Associate Professor Morten Hostrup, a leading authority on β2-adrenergic receptor signaling in skeletal muscle at the University of Copenhagen, to evaluate muscle […] The post Atrogi announces first subjects dosed in human trial f…